Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 228

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 228
---
, in whole or in part, during the four and one-half (4.5) year period commencing
180 days from the commencement of sales of the securities in this offering. The Representatives Warrants will provide for registration
rights (including a one-time demand registration right and unlimited piggyback rights) and customary anti-dilution provisions (for stock
dividends and splits and recapitalizations) consistent with FINRA Rule 5110, and further, the number of shares underlying the Representative’s
Warrants shall be reduced if necessary to comply with FINRA rules or regulations.

<div align='center'>137</div>

The Representative’s
Warrants are deemed underwriter compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1).
The Representative (or permitted assignees under Rule 5110(g)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants
or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from commencement
of sales in this offering. In addition, the Representative’s Warrants provide for registration rights upon request, in certain cases.
The one-time demand registration right provided will not be greater than five years from the commencement of sales of this offering in
compliance with FINRA Rule 5110(f)(2)(G)(iv). The piggyback registration right provided will not be greater than seven years from the
commencement of sales of this offering in compliance with FINRA Rule 5110(g)(8). We will bear all fees and expenses attendant to registering
the securities issuable on exercise of the Representative’s Warrants other than underwriting commissions incurred and payable by
the holders. The exercise price and number of shares issuable upon exercise of the Representative’s Warrants may be adjusted in
certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger, or consolidation. However,
neither the Representative Warrant exercise price, nor the number of Ordinary Shares underlying such warrants, will be adjusted for issuances
of Ordinary Shares by us at a price below the exercise price of the Representative’s Warrants.

Discretionary Accounts

The underwriters do not intend
to confirm sales of the securities offered hereby to any accounts over which they have